ATA-200 Dose-escalation Gene Therapy Trial in Patients with LGMDR5

Last updated: February 12, 2025
Sponsor: Atamyo Therapeutics
Overall Status: Active - Recruiting

Phase

1/2

Condition

N/A

Treatment

ATA-200

Clinical Study ID

NCT05973630
ATA-003-GSAR
  • Ages 6-13
  • All Genders

Study Summary

The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5). Patients will be treated sequentially in 2 dose-cohorts.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed diagnosis of LGMDR5 before age of 10, based on clinical presentation andgenotyping

  • Ambulant male or female patients aged 6 to less than 12 years of age at screening

  • Able to perform the 10-meter walk test (10MWT) in less than 15 sec and to rise fromchair with or without arm support

Exclusion

Exclusion Criteria:

  • Detectable neutralizing antibodies against AAV8

  • Cardiomyopathy with left ventricular ejection fraction (LVEF) < 50%

  • Respiratory assistance

  • Concomitant medical condition that might interfere with LGMDR5 evolution

  • Acute illness within 4 weeks of anticipated IMP administration

  • Current participation in another clinical trial with investigational medicinalproduct

  • Previous participation in gene and cell therapy trials

  • Any condition that would contraindicate immunosuppressant treatment

  • Presence of any permanent items (e.g., metal braces) precluding undergoing MRI

  • Any vaccination 1 month prior to planned IMP administration

  • Serology consistent with HIV exposure or active hepatitis B or C infection

  • Grade 2 or higher lab abnormalities for liver function tests, creatinine, hemogramand coagulation

Study Design

Total Participants: 6
Treatment Group(s): 1
Primary Treatment: ATA-200
Phase: 1/2
Study Start date:
February 15, 2025
Estimated Completion Date:
January 31, 2032

Study Description

This is a multicenter Phase 1b assessing the safety and tolerability of 2 doses of ATA-200 for the treatment of LGMDR5.

The dose escalation phase will enroll ambulant patients with LGMDR5. Two dose cohorts (C1) and (C2) will be enrolled sequentially and enrollment will be staggered with at least 4-week interval between 2 patient treatments. An initial cohort C1 of three (3) patients will receive a potentially effective dose corresponding to the minimum effective dose (MED) in preclinical studies.

Enrollment of three (3) patients in the 2nd higher dose cohort C2 (with a 7-fold safety margin relative to the highest safe dose in the GLP toxicology study) will be initiated following review of the one-month safety data post-administration in cohort C1 by an independent Data Safety Monitoring Board (DSMB).

Time point of primary interest for safety evaluation and dose selection for future studies is at 6 months.

All subjects will be followed up for an additional 4.5 years after completion of the evaluation period.

Connect with a study center

  • Hopital Trousseau

    Paris,
    France

    Site Not Available

  • Ospedale Maggiore Policlinico

    Milano,
    Italy

    Site Not Available

  • Child Health Research Institute

    Gainsville, Florida 32610
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.